Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Drug Targets. 2004 Nov;5(8):683-9.

Killing the messenger: antisense DNA and siRNA.

Author information

  • 1Cellular Biochem. Section, BRL, CCR, National Cancer Institute, Head, NIH Therapeutic Oligo. Int. Group, Bldg. 10, Rm. 5B05, 9000 Rockville Pike, Bethesda, MD 20892-1750, USA.

Abstract

Among the technologies available for gene knockdown RNase H-dependent antisense oligonucleotides and RNAi are very popular. Both offer specificity and efficient knockdown of the genes; both are useful tools to study gene functions. Antisense and RNAi methods share many practical problems such as site selection, toxicity at high concentration, and the difficulty of transfection in certain cell types. We will focus in this review on the most important issues in the development of both methods and their possible use in gene-silencing therapy.

PMID:
15578949
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Bentham Science Publishers Ltd.
    Loading ...
    Support Center